These findings collectively demonstrate that endogenous overexpression of FGF10 improves cognitive and synaptic deficits in 3xTg‐AD mice, indicating the beneficial effects of AAV‐mFGF10 treatment on cognitive and synaptic deficits in AD. This evidence concerns the gene FGF10 and Alzheimer disease.